Cargando…

Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation

Celecoxib (CXB) is a Biopharmaceutical Classification System (BCS) Class II molecule with high permeability that is practically insoluble in water. Because of the poor water solubility, there is a wide range of absorption and limited bioavailability following oral administration. These unfavorable p...

Descripción completa

Detalles Bibliográficos
Autores principales: Arslan, Aslıhan, Yet, Barbaros, Nemutlu, Emirhan, Akdağ Çaylı, Yağmur, Eroğlu, Hakan, Öner, Levent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964073/
https://www.ncbi.nlm.nih.gov/pubmed/36839685
http://dx.doi.org/10.3390/pharmaceutics15020363
_version_ 1784896412534702080
author Arslan, Aslıhan
Yet, Barbaros
Nemutlu, Emirhan
Akdağ Çaylı, Yağmur
Eroğlu, Hakan
Öner, Levent
author_facet Arslan, Aslıhan
Yet, Barbaros
Nemutlu, Emirhan
Akdağ Çaylı, Yağmur
Eroğlu, Hakan
Öner, Levent
author_sort Arslan, Aslıhan
collection PubMed
description Celecoxib (CXB) is a Biopharmaceutical Classification System (BCS) Class II molecule with high permeability that is practically insoluble in water. Because of the poor water solubility, there is a wide range of absorption and limited bioavailability following oral administration. These unfavorable properties can be improved using dry co-milling technology, which is an industrial applicable technology. The purpose of this study was to develop and optimize CXB nanoformulations prepared by dry co-milling technology, with a quality by design approach to maintain enhanced solubility, dissolution rate, and oral bioavailability. The resulting co-milled CXB composition using povidone (PVP), mannitol (MAN) and sodium lauryl sulfate (SLS) showed the maximum solubility and dissolution rate in physiologically relevant media. Potential risk factors were determined with an Ishikawa diagram, important risk factors were selected with Plackett-Burman experimental design, and CXB compositions were optimized with Central Composite design (CCD) and Bayesian optimization (BO). Physical characterization, intrinsic dissolution rate, solubility, and stability experiments were used to evaluate the optimized co-milled CXB compositions. Dissolution and permeability studies were carried out for the resulting CXB nanoformulation. Oral pharmacokinetic studies of the CXB nanoformulation and reference product were performed in rats. The results of in vitro and in vivo studies show that the CXB nanoformulations have enhanced solubility (over 4.8-fold (8.6 ± 1.06 µg/mL vs. 1.8 ± 0.33 µg/mL) in water when compared with celecoxib pure powder), and dissolution rate (at least 85% of celecoxib is dissolved in 20 min), and improved oral pharmacokinetic profile (the relative bioavailability was 145.2%, compared to that of Celebrex(®), and faster t(max) 3.80 ± 2.28 h vs. 6.00 ± 3.67 h, indicating a more rapid absorption rate).
format Online
Article
Text
id pubmed-9964073
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99640732023-02-26 Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation Arslan, Aslıhan Yet, Barbaros Nemutlu, Emirhan Akdağ Çaylı, Yağmur Eroğlu, Hakan Öner, Levent Pharmaceutics Article Celecoxib (CXB) is a Biopharmaceutical Classification System (BCS) Class II molecule with high permeability that is practically insoluble in water. Because of the poor water solubility, there is a wide range of absorption and limited bioavailability following oral administration. These unfavorable properties can be improved using dry co-milling technology, which is an industrial applicable technology. The purpose of this study was to develop and optimize CXB nanoformulations prepared by dry co-milling technology, with a quality by design approach to maintain enhanced solubility, dissolution rate, and oral bioavailability. The resulting co-milled CXB composition using povidone (PVP), mannitol (MAN) and sodium lauryl sulfate (SLS) showed the maximum solubility and dissolution rate in physiologically relevant media. Potential risk factors were determined with an Ishikawa diagram, important risk factors were selected with Plackett-Burman experimental design, and CXB compositions were optimized with Central Composite design (CCD) and Bayesian optimization (BO). Physical characterization, intrinsic dissolution rate, solubility, and stability experiments were used to evaluate the optimized co-milled CXB compositions. Dissolution and permeability studies were carried out for the resulting CXB nanoformulation. Oral pharmacokinetic studies of the CXB nanoformulation and reference product were performed in rats. The results of in vitro and in vivo studies show that the CXB nanoformulations have enhanced solubility (over 4.8-fold (8.6 ± 1.06 µg/mL vs. 1.8 ± 0.33 µg/mL) in water when compared with celecoxib pure powder), and dissolution rate (at least 85% of celecoxib is dissolved in 20 min), and improved oral pharmacokinetic profile (the relative bioavailability was 145.2%, compared to that of Celebrex(®), and faster t(max) 3.80 ± 2.28 h vs. 6.00 ± 3.67 h, indicating a more rapid absorption rate). MDPI 2023-01-20 /pmc/articles/PMC9964073/ /pubmed/36839685 http://dx.doi.org/10.3390/pharmaceutics15020363 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Arslan, Aslıhan
Yet, Barbaros
Nemutlu, Emirhan
Akdağ Çaylı, Yağmur
Eroğlu, Hakan
Öner, Levent
Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation
title Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation
title_full Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation
title_fullStr Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation
title_full_unstemmed Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation
title_short Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation
title_sort celecoxib nanoformulations with enhanced solubility, dissolution rate, and oral bioavailability: experimental approaches over in vitro/in vivo evaluation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964073/
https://www.ncbi.nlm.nih.gov/pubmed/36839685
http://dx.doi.org/10.3390/pharmaceutics15020363
work_keys_str_mv AT arslanaslıhan celecoxibnanoformulationswithenhancedsolubilitydissolutionrateandoralbioavailabilityexperimentalapproachesoverinvitroinvivoevaluation
AT yetbarbaros celecoxibnanoformulationswithenhancedsolubilitydissolutionrateandoralbioavailabilityexperimentalapproachesoverinvitroinvivoevaluation
AT nemutluemirhan celecoxibnanoformulationswithenhancedsolubilitydissolutionrateandoralbioavailabilityexperimentalapproachesoverinvitroinvivoevaluation
AT akdagcaylıyagmur celecoxibnanoformulationswithenhancedsolubilitydissolutionrateandoralbioavailabilityexperimentalapproachesoverinvitroinvivoevaluation
AT erogluhakan celecoxibnanoformulationswithenhancedsolubilitydissolutionrateandoralbioavailabilityexperimentalapproachesoverinvitroinvivoevaluation
AT onerlevent celecoxibnanoformulationswithenhancedsolubilitydissolutionrateandoralbioavailabilityexperimentalapproachesoverinvitroinvivoevaluation